Bracco, ImaRx Pharma, Molecular Biosystems, Sonus regulatory update

The FDA postponed its scheduled June 30 advisory committee meeting to discuss SNUS's NDA to market EchoGen ultrasound contrast enhancing agent.

Read the full 219 word article

How to gain access

Continue reading with a
two-week free trial.